Liquid Biopsy for the Detection and Management of Surgically Resectable Tumors

Overview

Journal Langenbecks Arch Surg

Specialty General Surgery

Date 2019 Aug 7

PMID 31385024

Citations 3

Authors

Barbara Aldana Blanco

Christopher L Wolfgang

Affiliations

Soon will be listed here.

Abstract

Background: Traditional biopsies have numerous limitations in the developing era of precision medicine, with cancer treatment that relies on biomarkers to guide therapy. Tumor heterogeneity raises the potential for sampling error with the use of traditional biopsy of the primary tumor. Moreover, tumors continuously evolve as new clones arise in the natural course of the disease and under the pressure of treatment. Since traditional biopsy is invasive, it is neither feasible nor practical to perform serial biopsies to guide treatment in real time.

Purpose: The current manuscript will review the most commonly used types of liquid biopsy and how these apply to surgical patients in terms of diagnosis, prediction of outcome, and guiding therapy.

Conclusions: Liquid biopsy has the potential to overcome many of the limitations of traditional biopsy as a highly tailored, minimally invasive, and cost-effective method to screen and monitor response to treatment. However, many challenges still need to be overcome before liquid biopsy becomes a reliable and widely available option.

Citing Articles

The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study.

Kodada D, Hyblova M, Krumpolec P, Janostiakova N, Barath P, Grendar M Int J Mol Sci. 2023; 24(9).

PMID: 37175518 PMC: 10178554. DOI: 10.3390/ijms24097811.

Is liquid biopsy mature enough for the diagnosis of Alzheimer's disease?.

Gong X, Zhang H, Liu X, Liu Y, Liu J, Fapohunda F Front Aging Neurosci. 2022; 14:977999.

PMID: 35992602 PMC: 9389010. DOI: 10.3389/fnagi.2022.977999.

Liquid Biopsy in Melanoma: Significance in Diagnostics, Prediction and Treatment Monitoring.

Kaminska P, Buszka K, Zabel M, Nowicki M, Alix-Panabieres C, Budna-Tukan J Int J Mol Sci. 2021; 22(18).

PMID: 34575876 PMC: 8468624. DOI: 10.3390/ijms22189714.

References

Hirsch F, Franklin W, Veve R, Varella-Garcia M, Bunn Jr P . HER2/neu expression in malignant lung tumors. Semin Oncol. 2002; 29(1 Suppl 4):51-8. DOI: 10.1053/sonc.2002.31523. View

Thiery J . Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002; 2(6):442-54. DOI: 10.1038/nrc822. View

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

Allard W, Matera J, Miller M, Repollet M, Connelly M, Rao C . Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004; 10(20):6897-904. DOI: 10.1158/1078-0432.CCR-04-0378. View

Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S . Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005; 102(45):16368-73. PMC: 1283450. DOI: 10.1073/pnas.0507904102. View

Lee J, Dedhar S, Kalluri R, Thompson E . The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006; 172(7):973-81. PMC: 2063755. DOI: 10.1083/jcb.200601018. View

Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B . Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007; 13(3):920-8. DOI: 10.1158/1078-0432.CCR-06-1695. View

Schmidt K, Diehl F . A blood-based DNA test for colorectal cancer screening. Discov Med. 2007; 7(37):7-12. View

Maheswaran S, Sequist L, Nagrath S, Ulkus L, Brannigan B, Collura C . Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008; 359(4):366-77. PMC: 3551471. DOI: 10.1056/NEJMoa0800668. View

10.

Kirsch C, Weickmann S, Schmidt B, Fleischhacker M . An improved method for the isolation of free-circulating plasma DNA and cell-free DNA from other body fluids. Ann N Y Acad Sci. 2008; 1137:135-9. DOI: 10.1196/annals.1448.035. View

11.

Mandel P, Metais P . Nuclear Acids In Human Blood Plasma. C R Seances Soc Biol Fil. 1948; 142(3-4):241-3. View

12.

Jiang Y, Palma J, Agus D, Wang Y, Gross M . Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem. 2010; 56(9):1492-5. DOI: 10.1373/clinchem.2010.143297. View

13.

Wilking U, Karlsson E, Skoog L, Hatschek T, Lidbrink E, Elmberger G . HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res Treat. 2010; 125(2):553-61. DOI: 10.1007/s10549-010-1029-2. View

14.

Sakaizawa K, Goto Y, Kiniwa Y, Uchiyama A, Harada K, Shimada S . Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br J Cancer. 2012; 106(5):939-46. PMC: 3305957. DOI: 10.1038/bjc.2012.12. View

15.

Gerlinger M, Rowan A, Horswell S, Math M, Larkin J, Endesfelder D . Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366(10):883-892. PMC: 4878653. DOI: 10.1056/NEJMoa1113205. View

16.

Vashist Y, Effenberger K, Vettorazzi E, Riethdorf S, Yekebas E, Izbicki J . Disseminated tumor cells in bone marrow and the natural course of resected esophageal cancer. Ann Surg. 2012; 255(6):1105-12. DOI: 10.1097/SLA.0b013e3182565b0b. View

17.

Forshew T, Murtaza M, Parkinson C, Gale D, Tsui D, Kaper F . Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012; 4(136):136ra68. DOI: 10.1126/scitranslmed.3003726. View

18.

Saucedo-Zeni N, Mewes S, Niestroj R, Gasiorowski L, Murawa D, Nowaczyk P . A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int J Oncol. 2012; 41(4):1241-50. PMC: 3583719. DOI: 10.3892/ijo.2012.1557. View

19.

Augustsson P, Magnusson C, Nordin M, Lilja H, Laurell T . Microfluidic, label-free enrichment of prostate cancer cells in blood based on acoustophoresis. Anal Chem. 2012; 84(18):7954-62. PMC: 3445767. DOI: 10.1021/ac301723s. View

20.

Perkins G, Yap T, Pope L, Cassidy A, Dukes J, Riisnaes R . Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One. 2012; 7(11):e47020. PMC: 3492590. DOI: 10.1371/journal.pone.0047020. View